Lindis Blood Care — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Lindis Blood Care is a private, clinical-stage MedTech company pioneering the Antibody-Based Cell Removal Technology (ABCR-T) platform. Its lead product, CATUVAB®, is a medical device designed to enable safe autologous blood transfusion in oncological surgeries by removing tumor cells from salvaged blood, thereby reducing reliance on donor blood. The company has completed a pivotal multicenter study (REMOVE) with 136 patients, is preparing for an EU launch in Q4 2025, and is actively seeking distribution and licensing partners globally. Lindis Blood Care operates in the hematology and medical device sectors, addressing a critical need in surgical oncology and transfusion medicine.

OncologyHematology

Technology Platform

Antibody-Based Cell Removal Technology (ABCR-T): A proprietary platform using a trifunctional antibody to selectively bind and aggregate target cells (e.g., tumor cells, immune cells), enabling their removal via standard blood filtration.

Opportunities

The primary opportunity is unlocking the use of safe autologous blood transfusion in cancer surgery, a large market currently reliant on risky donor blood.

The ABCR-T platform also has potential for expansion into other areas requiring selective cell removal from blood, such as transplant medicine or treatment of autoimmune diseases.

Risk Factors

Key risks include delays in regulatory approval or market launch, challenges in achieving clinical adoption and securing reimbursement from healthcare systems, and potential competition from other blood-processing technologies.

Long-term clinical data proving impact on cancer recurrence rates is also needed.

Competitive Landscape

Lindis competes in the niche of intraoperative blood salvage and blood safety. Direct competition may come from other companies developing tumor cell filtration technologies, while indirect competition includes improvements in donor blood screening and alternative blood substitutes. Its proprietary antibody-based approach appears to be a differentiating factor.

More companies in Biologics / Biosimilars →More companies in Germany →